The Short Answer
Retatrutide is Eli Lilly's investigational "triple G agonist" — the first molecule to simultaneously activate GIP, GLP-1, and glucagon receptors. It's producing the highest weight loss numbers ever recorded in clinical trials: up to 28.7% average body weight reduction at 68 weeks in Phase 3 (TRIUMPH-4), with Phase 2 data suggesting even greater potential at higher doses and longer durations.
Currently in Phase 3 trials across multiple indications including obesity, type 2 diabetes, knee osteoarthritis, sleep apnea, and liver disease, retatrutide represents the next evolutionary leap beyond dual agonists like tirzepatide. FDA approval is projected for approximately 2027.
What Is Retatrutide?
While tirzepatide (Mounjaro/Zepbound) proved that targeting two hormone receptors is better than one, Eli Lilly asked the obvious next question: what happens when you target three?
Retatrutide (development code LY3437943) is the answer — a single-molecule triple agonist that activates three metabolic receptors simultaneously:
- GIP (glucose-dependent insulinotropic polypeptide)
- GLP-1 (glucagon-like peptide-1)
- Glucagon receptor
This triple mechanism makes retatrutide unique in the current obesity pharmacology landscape. While CagriSema pairs amylin with GLP-1, and tirzepatide pairs GIP with GLP-1, retatrutide is the only agent adding direct glucagon receptor activation — a pathway that fundamentally changes the metabolic equation.
The Triple Mechanism: Why Glucagon Changes Everything
GIP and GLP-1: The Foundation
Retatrutide shares the dual GIP/GLP-1 mechanism with tirzepatide, producing the well-established benefits:
- Appetite suppression through hypothalamic signaling (GLP-1)
- Enhanced insulin secretion in a glucose-dependent manner (both GIP and GLP-1)
- Improved insulin sensitivity and beta-cell function (GIP)
- Slowed gastric emptying for extended satiety (GLP-1)
- Reduced food reward and cravings (GLP-1)
Glucagon: The Third Lever
This is what sets retatrutide apart. Glucagon receptor activation adds mechanisms that neither GIP nor GLP-1 provide:
Increased energy expenditure: Glucagon stimulates thermogenesis — the body's process of converting stored energy into heat. This means retatrutide doesn't just reduce calorie intake (like GLP-1 agonists) but also increases calorie burning. In metabolic studies, glucagon receptor activation has been shown to raise resting energy expenditure by 5-15%.
Enhanced hepatic lipid oxidation: Glucagon directly signals the liver to oxidize (burn) fatty acids rather than store them. This has profound implications for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), where excess liver fat drives disease progression.
Improved lipid metabolism: Glucagon receptor activation reduces circulating triglycerides and promotes a more favorable lipid profile, contributing to cardiovascular risk reduction.
Mobilization of fat stores: While GLP-1 primarily reduces appetite, glucagon actively promotes the breakdown of adipose tissue — essentially telling the body to use its stored fat as fuel.
The Synergistic Triad
The three pathways don't just add up — they amplify each other:
- GLP-1 suppresses appetite → you eat less
- GIP enhances insulin function → nutrients are processed more efficiently
- Glucagon increases energy expenditure → you burn more at rest
- Combined: both sides of the energy balance equation are addressed simultaneously
This dual-sided approach — reducing intake AND increasing expenditure — is the leading hypothesis for why retatrutide produces higher weight loss numbers than dual agonists alone.
Clinical Trial Results: The TRIUMPH Program
Phase 2: Record-Setting Weight Loss
The Phase 2 trial, published in The New England Journal of Medicine in 2023, established retatrutide as a serious contender with unprecedented efficacy data.
Key results at 48 weeks (793 participants):
| Dose | Weight Loss | Participants Achieving ≥15% Loss |
|---|---|---|
| 1 mg | -8.7% | ~28% |
| 4 mg (initial), then 4 mg | -17.1% | ~64% |
| 4 mg (initial), then 8 mg | -22.8% | ~75% |
| 4 mg (initial), then 12 mg | -24.2% | ~83% |
| Placebo | -2.1% | ~5% |
The 24.2% weight loss at the highest dose over just 48 weeks — with the weight loss curve still trending downward at trial end — suggested that longer treatment durations could yield even greater reductions.
Phase 3 TRIUMPH-4: Obesity with Knee Osteoarthritis
The first Phase 3 results were announced in December 2025, evaluating the two highest doses (9 mg and 12 mg) in adults with obesity and knee osteoarthritis.
Key results at 68 weeks (445 participants):
| Endpoint | Retatrutide 9 mg | Retatrutide 12 mg | Placebo |
|---|---|---|---|
| Weight loss | -20.0% (-50.5 lbs) | -23.7% (-60.0 lbs) | -4.6% |
| Max weight loss | — | -28.7% (71.2 lbs) | — |
| WOMAC pain score improvement | -4.5 points | -4.4 points | -2.4 points |
| Pain-free at week 68 | 14.1% | 12.0% | 4.2% |
| Systolic BP reduction | Significant | -14.0 mmHg | Modest |
The headline number — up to 28.7% weight loss, equivalent to an average of 71.2 lbs — represents the highest weight loss figure ever reported in a Phase 3 obesity trial.
Beyond weight, retatrutide also demonstrated significant improvements in osteoarthritis pain and cardiovascular risk markers including non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein.
The Broader TRIUMPH Program
Six additional Phase 3 trials are ongoing, with results expected through 2026:
| Trial | Indication | Key Focus |
|---|---|---|
| TRIUMPH-1 | Obesity (general) | Primary efficacy trial — 80 weeks, may show >30% weight loss |
| TRIUMPH-2 | Type 2 diabetes | Glycemic control + weight loss |
| TRIUMPH-3 | Obesity (general) | Additional efficacy data |
| TRIUMPH-4 | Obesity + knee OA | ✅ First results Dec 2025 |
| TRIUMPH-5 | Sleep apnea | AHI reduction + weight loss |
| TRIUMPH-MASLD | Liver disease | Liver fat reduction + fibrosis improvement |
| Cardiovascular outcomes | CVD risk | Long-term MACE reduction |
The breadth of this program reflects Eli Lilly's confidence in retatrutide's multi-system metabolic benefits.
Side Effect Profile
Common Side Effects
Retatrutide's side effect profile is dominated by gastrointestinal symptoms, consistent with the GLP-1 agonist class but somewhat higher in frequency:
| Side Effect | 9 mg | 12 mg | Placebo |
|---|---|---|---|
| Nausea | 38.1% | 43.2% | — |
| Diarrhea | 34.7% | 33.1% | — |
| Constipation | 21.8% | 25.0% | — |
| Vomiting | 20.4% | 20.9% | — |
These rates are somewhat higher than what's seen with tirzepatide, likely attributable to the additive effects of triple receptor activation on the gastrointestinal system.
Emerging Safety Signal: Dysesthesia
A notable new finding in TRIUMPH-4 was dysesthesia — an abnormal sense of touch where normal sensations feel unusual or uncomfortable. This was reported in 8.8% (9 mg) and 20.9% (12 mg) of patients, compared to just 0.7% with placebo.
This side effect was not observed in Phase 2 trials and warrants monitoring. Importantly, it did not appear to drive treatment discontinuation, suggesting it was manageable in severity.
The mechanism is not fully understood. One hypothesis is that glucagon receptor activation may affect peripheral nerve signaling, though this remains speculative. Additional data from the broader TRIUMPH program will help characterize this signal.
Discontinuation Rates
Discontinuation due to adverse events was 12.2% (9 mg) and 18.2% (12 mg) compared to 4.0% with placebo. Notably, Eli Lilly reported that discontinuation rates were correlated with baseline BMI and included cases of "perceived excessive weight loss" — suggesting some patients stopped treatment because they were losing too much weight, not because of side effects.
For patients with baseline BMI ≥35, discontinuation rates were lower: 8.8% (9 mg) and 12.1% (12 mg).
Retatrutide vs. the Competition
| Feature | Retatrutide 12 mg | Tirzepatide 15 mg | CagriSema | Semaglutide 2.4 mg |
|---|---|---|---|---|
| Mechanism | GIP + GLP-1 + Glucagon | GIP + GLP-1 | Amylin + GLP-1 | GLP-1 only |
| Max Phase 3 Weight Loss | ~28.7% | ~22-26% | ~22.7% | ~15-17% |
| Route | Weekly injection | Weekly injection | Weekly injection | Weekly injection |
| Unique Benefit | Increased energy expenditure | Proven cardiovascular outcomes | Dual satiety pathways | Widest evidence base |
| Key Concern | Dysesthesia signal | GI side effects | Slightly below expectations | Weight plateau |
| Developer | Eli Lilly | Eli Lilly | Novo Nordisk | Novo Nordisk |
| Status | Phase 3 | Approved | NDA filed | Approved |
Who Might Benefit from Retatrutide?
Based on its mechanism and clinical data, retatrutide may be particularly valuable for:
Strongest candidates:
- Adults with severe obesity (BMI ≥40) where maximal weight loss is critical
- Patients with obesity-related comorbidities requiring aggressive metabolic intervention
- Adults with metabolic dysfunction-associated liver disease (MASLD/NAFLD)
- Patients who've plateaued on GLP-1 or dual agonist therapy
- Those with obesity plus knee osteoarthritis or sleep apnea
Less ideal candidates:
- Patients with unexplained peripheral nerve symptoms
- Those who experienced intolerable GI side effects on lower-potency GLP-1 agents
- Patients seeking modest weight management rather than aggressive loss
Timeline and Market Outlook
- December 2025: First Phase 3 results (TRIUMPH-4) announced
- 2026: Results from remaining TRIUMPH studies expected
- 2026-2027: Anticipated NDA submission to FDA
- ~2027: Projected FDA approval and market launch
- 2031: Projected sales of $15.6 billion (GlobalData estimate)
Market analysts view retatrutide as potentially the most potent weight-loss medication in Eli Lilly's pipeline. Combined with tirzepatide (Mounjaro/Zepbound) and orforglipron (oral GLP-1), Lilly's obesity portfolio is projected to reach over $100 billion in peak worldwide sales.
The Bottom Line
Retatrutide represents the most aggressive pharmacological approach to obesity currently in late-stage development. By adding glucagon receptor activation to the proven GIP/GLP-1 dual mechanism, it achieves weight loss figures that seemed impossible just a few years ago — nearly 29% in Phase 3, with potential for 30%+ in longer-duration trials.
The trade-off is a more complex side effect profile, including a novel dysesthesia signal that will need careful monitoring. But for patients with severe obesity and its cascading health consequences, retatrutide's risk-benefit profile may be compelling.
If TRIUMPH-1 delivers ≥30% weight loss at 80 weeks — which analysts consider likely — retatrutide will establish a new benchmark for pharmacological obesity treatment and further reshape the competitive landscape between Eli Lilly and Novo Nordisk.
Frequently Asked Questions
What makes retatrutide different from tirzepatide (Zepbound)?
Both are Eli Lilly products and share GIP and GLP-1 activity. Retatrutide adds a third mechanism — glucagon receptor activation — which increases energy expenditure and enhances liver fat burning. This triple action produces higher weight loss numbers (~29% vs. ~22-26%).
When will retatrutide be available?
Retatrutide is currently in Phase 3 trials. FDA approval is projected for approximately 2027, with market launch expected shortly after. Results from the key TRIUMPH studies are expected throughout 2026.
Is 28.7% weight loss safe?
The weight loss observed with retatrutide occurs gradually over 68+ weeks and is associated with improvements in metabolic markers, blood pressure, and inflammatory markers. Physicians will monitor patients closely, and dose adjustments can be made. Some TRIUMPH-4 participants discontinued treatment due to perceived excessive weight loss, highlighting the potency.
What is dysesthesia and should I be concerned?
Dysesthesia is an abnormal sensation where normal touch feels unusual or uncomfortable. It was reported in up to 20.9% of patients on the highest dose. While the signal warrants monitoring, it did not appear to cause treatment discontinuation in the trial. More data is expected from additional Phase 3 studies.
How does retatrutide compare to CagriSema?
They take different approaches: retatrutide activates GIP + GLP-1 + glucagon receptors, while CagriSema combines amylin + GLP-1 signaling. Phase 3 data suggests retatrutide may produce slightly higher weight loss (~29% vs. ~23%), but no head-to-head trial exists. The choice will likely depend on individual patient factors and tolerability.
References
- Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 2023;389:514-526.
- Eli Lilly. "Lilly's triple agonist, retatrutide, delivered weight loss of up to 71.2 lbs in first successful Phase 3 trial." Press Release, December 11, 2025.
- TRIUMPH-4 Clinical Trial Results. ClinicalTrials.gov: NCT05931367.
- Sattar N, et al. "Retatrutide—A Game Changer in Obesity Pharmacotherapy." PMC. 2024.
- GlobalData Pharmaceutical Intelligence. Retatrutide Market Forecast 2025-2031.
This article is for informational and educational purposes only. It is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. PeptideIQ does not endorse or promote the use of any specific drug or treatment.
Last updated: February 2026